1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Leighl, N. B., Shu, C. A., Minchom, A., Felip, E., Cousin, S., Cho, B. C., Park, K., Han, J.-Y., Boyer, M., Lee, C. K., Garcia, V. M., Tomasini, P., Viteri, S., Xie, J., Mertz, J., Artis, E., Schnepp, R. W., Knoblauch, R. E., Thayu, M., & Perez, J. M. T. (2021). 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Annals of Oncology, 32, S951–S952. https://doi.org/10.1016/j.annonc.2021.08.1797
Authors:
N. B. Leighl
Catherine A. Shu
Anna Minchom
Enriqueta Felip
Sophie Cousin
B.C. Cho
K. Park
J-Y. Han
Michael Boyer
C.K. Lee
Víctor Moreno
Pascale Tomasini
Santiago Viteri
Juanjuan Xie
Jennifer A. Mertz
Eunice Artis
Robert W. Schnepp
R.E. Knoblauch
Meena Thayu
J.M. Trigo Perez
Affiliated Authors:
Catherine A. Shu
Columbia Affiliation:
Subjects:
Advancements in Lung Cancer Research (OpenAlex Topic)
Gastric Cancer Research and Treatment (OpenAlex Topic)
Small Cell Lung Cancer (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2021.08.1797
DOI:
10.1016/j.annonc.2021.08.1797
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: